362 related articles for article (PubMed ID: 25400761)
1. Association between molecular subtypes and lymph node status in invasive breast cancer.
Si C; Jin Y; Wang H; Zou Q
Int J Clin Exp Pathol; 2014; 7(10):6800-6. PubMed ID: 25400761
[TBL] [Abstract][Full Text] [Related]
2. Unexpected features of breast cancer subtype.
Liu YH; Wang OC; Chen ED; Cai YF; Pan CM; Yang F; Zhang XH
World J Surg Oncol; 2015 Aug; 13():249. PubMed ID: 26271634
[TBL] [Abstract][Full Text] [Related]
3. Predictive parameters for internal mammary node drainage in patients with early breast cancer.
Lukesova L; Vrana D; Gatek J; Koranda P; Cwiertka K; Radova L; Melichar B; Prouzova Z; Sramek V; Svach I
Tumori; 2014; 100(3):254-8. PubMed ID: 25076234
[TBL] [Abstract][Full Text] [Related]
4. The maximum standardized uptake value of metastatic site in 18 F-FDG PET/CT predicts molecular subtypes and survival in metastatic breast cancer: An Izmir Oncology Group study.
Cokmert S; Tanriverdi O; Karapolat I; Demir L; Bayoglu V; Can A; Akyol M; Yilmaz Y; Oktay Tarhan M
J BUON; 2016; 21(6):1410-1418. PubMed ID: 28039701
[TBL] [Abstract][Full Text] [Related]
5. Basal breast cancer molecular subtype predicts for lower incidence of axillary lymph node metastases in primary breast cancer.
Crabb SJ; Cheang MC; Leung S; Immonen T; Nielsen TO; Huntsman DD; Bajdik CD; Chia SK
Clin Breast Cancer; 2008 Jun; 8(3):249-56. PubMed ID: 18650155
[TBL] [Abstract][Full Text] [Related]
6. Is biological subtype prognostic of locoregional recurrence risk in women with pT1-2N0 breast cancer treated with mastectomy?
Truong PT; Sadek BT; Lesperance MF; Alexander CS; Shenouda M; Raad RA; Taghian AG
Int J Radiat Oncol Biol Phys; 2014 Jan; 88(1):57-64. PubMed ID: 24161421
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Factors on the Positivity for Metastases of the Axillary Lymph Nodes from Primary Breast Cancer.
Kondov B; Kondov G; Spirovski Z; Milenkovikj Z; Colanceski R; Petrusevska G; Pesevska M
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2017 Mar; 38(1):81-90. PubMed ID: 28593885
[TBL] [Abstract][Full Text] [Related]
8. Molecular phenotypes of DCIS predict overall and invasive recurrence.
Williams KE; Barnes NLP; Cramer A; Johnson R; Cheema K; Morris J; Howe M; Bundred NJ
Ann Oncol; 2015 May; 26(5):1019-1025. PubMed ID: 25678586
[TBL] [Abstract][Full Text] [Related]
9. Triple-negative breast cancer is not associated with increased likelihood of nodal metastases.
Gangi A; Mirocha J; Leong T; Giuliano AE
Ann Surg Oncol; 2014 Dec; 21(13):4098-103. PubMed ID: 25155393
[TBL] [Abstract][Full Text] [Related]
10. [Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer. Its relation with molecular subtypes].
Ruano R; Ramos M; García-Talavera JR; Ramos T; Rosero AS; González-Orus JM; Sancho M
Rev Esp Med Nucl Imagen Mol; 2014; 33(6):340-5. PubMed ID: 24856234
[TBL] [Abstract][Full Text] [Related]
11. Survival impact and predictive factors of axillary recurrence after sentinel biopsy.
Houvenaeghel G; Classe JM; Garbay JR; Giard S; Cohen M; Faure C; Charytansky H; Rouzier R; Daraï E; Hudry D; Azuar P; Villet R; Gimbergues P; Tunon de Lara C; Martino M; Fraisse J; Dravet F; Chauvet MP; Goncalves A; Lambaudie E
Eur J Cancer; 2016 May; 58():73-82. PubMed ID: 26971077
[TBL] [Abstract][Full Text] [Related]
12. Simple Prediction Model of Axillary Lymph Node Positivity After Analyzing Molecular and Clinical Factors in Early Breast Cancer.
Chung MJ; Lee JH; Kim SH; Suh YJ; Choi HJ
Medicine (Baltimore); 2016 May; 95(20):e3689. PubMed ID: 27196477
[TBL] [Abstract][Full Text] [Related]
13. Lymph node involvement in immunohistochemistry-based molecular classifications of breast cancer.
Howland NK; Driver TD; Sedrak MP; Wen X; Dong W; Hatch S; Eltorky MA; Chao C
J Surg Res; 2013 Dec; 185(2):697-703. PubMed ID: 24095025
[TBL] [Abstract][Full Text] [Related]
14. Receptor discordance rate and its effects on survival in primary and recurrent breast cancer patients.
Ilgun S; Sarsenov D; Erdogan Z; Ordu C; Celebi F; Nur Pilanci K; Ozturk A; Selamoglu D; Alco G; Aktepe F; Eralp Y; Tuzlali S; Ozmen V
J BUON; 2016; 21(6):1425-1432. PubMed ID: 28039703
[TBL] [Abstract][Full Text] [Related]
15. Does the subtype of breast cancer affect the diagnostic performance of axillary ultrasound for nodal staging in breast cancer patients?
Vane MLG; van Nijnatten TJA; Nelemans PJ; Lobbes MBI; van Roozendaal LM; Kooreman LFS; Keymeulen KBMI; Smidt ML; Schipper RJ
Eur J Surg Oncol; 2019 Apr; 45(4):573-577. PubMed ID: 30732971
[TBL] [Abstract][Full Text] [Related]
16. Breast cancer subtype approximations and loco-regional recurrence after immediate breast reconstruction.
Kneubil MC; Brollo J; Botteri E; Curigliano G; Rotmensz N; Goldhirsch A; Lohsiriwat V; Manconi A; Martella S; Santillo B; Petit JY; Rietjens M
Eur J Surg Oncol; 2013 Mar; 39(3):260-5. PubMed ID: 23313014
[TBL] [Abstract][Full Text] [Related]
17. Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry.
Park S; Koo JS; Kim MS; Park HS; Lee JS; Lee JS; Kim SI; Park BW
Breast; 2012 Feb; 21(1):50-7. PubMed ID: 21865043
[TBL] [Abstract][Full Text] [Related]
18. Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: triple positive tumours are more likely lymph node positive.
Van Calster B; Vanden Bempt I; Drijkoningen M; Pochet N; Cheng J; Van Huffel S; Hendrickx W; Decock J; Huang HJ; Leunen K; Amant F; Berteloot P; Paridaens R; Wildiers H; Van Limbergen E; Weltens C; Timmerman D; Van Gorp T; Smeets A; Van den Bogaert W; Vergote I; Christiaens MR; Neven P
Breast Cancer Res Treat; 2009 Jan; 113(1):181-7. PubMed ID: 18264760
[TBL] [Abstract][Full Text] [Related]
19. The Association between Molecular Subtypes of Breast Cancer with Histological Grade and Lymph Node Metastases in Indonesian Woman.
Setyawati Y; Rahmawati Y; Widodo I; Ghozali A; Purnomosari D
Asian Pac J Cancer Prev; 2018 May; 19(5):1263-1268. PubMed ID: 29801411
[TBL] [Abstract][Full Text] [Related]
20. Use of ER/PR/HER2 subtypes in conjunction with the 2007 St Gallen Consensus Statement for early breast cancer.
Bauer K; Parise C; Caggiano V
BMC Cancer; 2010 May; 10():228. PubMed ID: 20492696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
